Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Novikoff A, O'Brien SL, Bernecker M, Grandl G, Kleinert M, Knerr PJ, Stemmer K, Klingenspor M, Zeigerer A, DiMarchi R, Tschöp MH, Finan B, Calebiro D, Müller TD
Abstract
Objective We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide. Methods Receptor G protein recruitment and internalization/trafficking dynamics were assessed using bioluminescence resonance energy transfer (BRET)-based technology and live-cell HILO microscopy. Results Relative to native and acylated GLP-1 agonists, MAR709 and tirzepatide showed preserved maximal cAMP production despite partial Gα s recruitment paralleled by diminished ligand-induced receptor internalization at both target receptors. Despite MAR709's lower internalization rate, GLP-1R co-localization with Rab11-associated recycling endosomes was not different between MAR709 and GLP-1R specific mono-agonists. Conclusions Our data indicated that MAR709 and tirzepatide induce unique spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics relative to native peptides, semaglutide, and matched mono-agonist controls. These findings support the hypothesis that the structure of GLP-1/GIP dual-agonists confer a biased agonism that, in addition to its influence on intracellular signaling, uniquely modulates receptor trafficking.
Abstract of "Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists" by Novikoff A, O'Brien SL, Bernecker M et al., https://doi.org/10.1016/j.molmet.2021.101181, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.
Record
- Archive ID
- doi:10.1016/j.molmet.2021.101181
- Published
- Feb 6, 2021
- Venue
- Molecular metabolism
- DOI
- 10.1016/j.molmet.2021.101181
- PubMed
- 33556643
- PMC
- PMC7921015
- License
- CC-BY
- Provenance
- europepmc